Axa IM

Prioritising social considerations

Clément Bultheel and Benjamin Jacot

Simon King joins

Scope 1, 2 and 3 emissions

China is experiencing significant demographic shifts, and these are spurring its emergence as a new player in innovative health care, says AXA IM's Cinney Zhang.

Emerging technologies are helping to reshape treatments across healthcare and are bringing new opportunities for investors, says AXA IM's Linden Thomson.

Fuelled by innovation, the outlook for the biotech sector remains positive and should be viewed separately from the macro environment, says Peter Hughes.

Huge investment needed

No harmful emissions

Charles Fianko